GlaxoSmithKline (LON:GSK)‘s stock had its “hold” rating reissued by equities research analysts at Deutsche Bank in a research note issued on Tuesday. They presently have a GBX 1,525 ($19.93) price objective on the stock. Deutsche Bank’s price target indicates a potential upside of 6.63% from the company’s current price.
Several other research analysts also recently commented on GSK. Credit Suisse Group set a GBX 1,600 ($20.91) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Tuesday. HSBC lowered their target price on GlaxoSmithKline from GBX 2,030 ($26.53) to GBX 2,000 ($26.13) and set a “buy” rating for the company in a research note on Wednesday, November 28th. Liberum Capital downgraded GlaxoSmithKline from a “buy” rating to a “hold” rating and boosted their target price for the stock from GBX 1,630 ($21.30) to GBX 1,700 ($22.21) in a research note on Thursday, August 30th. Cfra set a GBX 1,620 ($21.17) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research note on Tuesday. Finally, Goldman Sachs Group set a GBX 1,900 ($24.83) target price on GlaxoSmithKline and gave the stock a “buy” rating in a research note on Monday. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company’s stock. GlaxoSmithKline has an average rating of “Hold” and an average target price of GBX 1,518.84 ($19.85).
Shares of LON GSK opened at GBX 1,430.20 ($18.69) on Tuesday. GlaxoSmithKline has a 12 month low of GBX 1,235.20 ($16.14) and a 12 month high of GBX 1,724.50 ($22.53).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Story: How Important is Technical Analysis of Stocks
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.